Kaliumklorid B. Braun

Potassium chloride, the active ingredient in Kaliumklorid B. Braun, is an electrolyte supplement presented as an intravenous solution for intravenous use. It is employed to correct low blood potassium levels and to maintain electrolyte balance in patients at risk of hypokalemia, especially in those receiving diuretic therapy or undergoing major surgery.

GNH USA supplies Kaliumklorid B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides reliable sourcing, regulatory support, and global logistics to ensure consistent product availability across diverse healthcare settings.

Kaliumklorid B. Braun is used to replace potassium in conditions that cause electrolyte depletion.

- Hypokalemia: restores normal serum potassium concentrations in patients with low potassium levels. - Potassium depletion: replenishes body stores during prolonged diuretic therapy or gastrointestinal losses. - Electrolyte replacement during intravenous therapy: provides potassium as part of balanced IV fluid regimens for critically ill patients.

Intravenous potassium chloride can be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Infusion site pain or irritation: mild discomfort at the injection site. - Nausea: transient feeling of sickness during or after infusion. - Tingling or paresthesia: temporary sensory changes in the extremities. - Mild hypotension: slight drop in blood pressure during rapid administration.

Serious or Rare Side Effects: - Severe hyperkalemia: dangerously high serum potassium that can cause cardiac arrhythmia. - Cardiac arrest or ventricular fibrillation: life‑threatening rhythm disturbances. - Anaphylactic reaction: severe allergic response requiring immediate intervention. - Tissue necrosis or phlebitis: severe local injury if extravasation occurs.

When using Kaliumklorid B. Braun, clinicians should observe several safety measures to minimize risk. - Renal impairment: monitor serum potassium and adjust infusion rate. - Cardiac disease: perform ECG monitoring during and after infusion. - Concomitant potassium‑sparing agents: avoid additive hyperkalemia risk. - Existing hyperkalemia: do not administer if serum K+ exceeds 5.5 mEq/L. - Rapid infusion: limit infusion rate to ≤10 mEq per hour to reduce cardiac irritation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Potassium chloride may interact with other medicines, altering potassium balance or cardiac function.

Major Interactions (Avoid): - ACE inhibitors or ARBs: increase risk of hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): additive potassium rise. - Trimethoprim‑sulfamethoxazole: can cause significant hyperkalemia. - NSAIDs (chronic use): reduce renal potassium excretion. - Heparin (long‑term): may induce hyperkalemia via aldosterone suppression.

Moderate Interactions (Monitor Closely): - Digoxin: heightened risk of digoxin toxicity with elevated potassium. - Lithium: altered lithium clearance, requiring serum level checks.